Our alumni from Tri-Institutional programs have successfully applied to Biotech Equity Research as well as Management and Life Sciences Consulting Firms. The following individuals have generously agreed to be featured here. Feel free to reach out to our alumni for career advice and opportunities.

Christina Ghenoiu

For the past three years Cristina Ghenoiu, Ph.D., was a Biotech Equity Research Associate Analyst at Cowen and Company, where she had over 20 biotech companies in her portfolio. In this role, she used her scientific training, financial modeling and critical thinking to derive investment decisions and analyze some of the latest advancements in medical science. This fall, Cristina will be heading to Menlo Park, CA, to serve as a Vice President at Longitude Capital, a venture capital fund focused on investing in biotech assets that have already shown proof-of-concept. Prior to Cowen, Cristina was a postdoctoral associate at Rockefeller University where she followed up on her doctoral work discovering a new activation mechanism involving two key anticancer drug targets. She has co-authored 7 scientific articles of which 3 as a first author in Molecular Cell, Science and JCB. Dr. Ghenoiu has a Ph.D. in Chromosome and Cell Biology from Weill Cornell Graduate School of Medical Sciences, and graduated magna cum laude with a B.A. in Biochemistry from Mount Holyoke College.

Biotech equity research description:
Biotech equity research analysts follow the progress of public biotechnology companies, and make stock recommendations to institutional investor clients.The position is a unique combination of science, medicine, and finance. It may be ideal for a person with passion in these areas. Job tasks include financial modeling, interviews with physician experts and company managements, conducting surveys, literature reviews, hosting industry conferences, writing reports and making oral presentations.What I find especially appealing about the job is that it involves acquiring expertise in a broad range of disciplines, both scientific (gaining in-depth knowledge of therapeutic areas pursued by covered companies, drug mechanisms and their associated safety/efficacy profiles, clinical trial design strategies, etc.) and non-scientific (analyzing intellectual property, financial status, market opportunities, etc.). This position is one of just a handful in which former physicians and scientists can apply their healthcare expertise to the art of investing. The product of our work is first and foremost good investment ideas.

Daniel Gilmer

Daniel Gilmer, Ph.D., is an Associate at McKinsey & Company, where he works on market access, pricing, transaction, and merger management in pharmaceuticals and medical products as well as strategy in healthcare systems and services. Prior to McKinsey, Daniel was a graduate fellow at Rockefeller University where he developed and patented a novel drug to treat antibiotic-resistant bacteria. He received his Ph.D. from Rockefeller University in 2014, and graduated summa cum laude with a B.S. in Biology from Howard University.